Results 1 to 10 of about 201 (100)

Current Perspectives on Letermovir and Maribavir for the Management of Cytomegalovirus Infection in Solid Organ Transplant Recipients

Drug Design, Development and Therapy
Raymund R Razonable1,2 1Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USACorrespondence ...
Raymund R Razonable
exaly   +2 more sources

Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients

Antiviral Therapy, 2022
Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant.
Aude Boignard, Caroline Augier, Mathilde Kheng, Olivier Epaulard, Raphaele Germi   +4 more
doaj   +1 more source

Cytomegalovirus Infection after Allogeneic Hematopoietic Cell Transplantation under 100-Day Letermovir Prophylaxis: A Real-World 1-Year Follow-Up Study

Viruses, 2023
The prevention and management of cytomegalovirus (CMV) reactivation is important to improve the outcomes of allogeneic hematopoietic cell transplantation (allo-HCT) recipients.
Dukhee Nho, Raeseok Lee, Sung-Yeon Cho, Dong-Gun Lee, Eun-Jin Kim, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Yoo-Jin Kim, Seok Lee, Hee-Je Kim   +10 more
doaj   +1 more source

Developing a mechanistic understanding of the nonlinear pharmacokinetics of letermovir and prospective drug interaction with everolimus using physiological‐based pharmacokinetic modeling

Clinical and Translational Science, 2023
Letermovir is approved for use in cytomegalovirus‐seropositive hematopoietic stem cell transplant recipients and is investigated in other transplant settings.
Karsten Menzel, Yuhsin Kuo, Dapeng Chen, Georgy Hartmann, Ying‐Hong Wang, Carolyn R. Cho, Jacqueline B. McCrea, Kazuhiko Asari   +7 more
doaj   +1 more source

Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study

Vaccines, 2021
Background: Real-life data on the administration of letermovir as cytomegalovirus (CMV) primary prophylaxis after allogeneic hematopoietic cell transplantation (HCT) remain limited. Methods: We conducted a retrospective single-center matched cohort study,
Léna Royston, Eva Royston, Stavroula Masouridi-Levrat, Nathalie Vernaz, Yves Chalandon, Christian Van Delden, Dionysios Neofytos   +6 more
doaj   +1 more source

Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis

Pharmacology Research & Perspectives, 2023
Tacrolimus interacts with letermovir and azole antifungals, whereas letermovir has nonuniform effects on the pharmacokinetics of azole antifungals.
Yuri Shinogi, Toshinori Hirai, Miki Ishibashi, Kazuko Ino, Isao Tawara, Takuya Iwamoto   +5 more
doaj   +1 more source

CD4+ T cells are the major predictor of HCMV control in allogeneic stem cell transplant recipients on letermovir prophylaxis

Frontiers in Immunology, 2023
IntroductionHuman cytomegalovirus (HCMV) causes significant morbidity and mortality in allogeneic stem cell transplant (alloSCT) recipients. Recently, antiviral letermovir prophylaxis during the first 100 days after alloSCT replaced PCR-guided preemptive
Chris David Lauruschkat, Ihsan Muchsin, Alice Rein, Florian Erhard, Denise Grathwohl, Lars Dölken, Lars Dölken, Carolin Köchel, Christine Susanne Falk, Christine Susanne Falk, Christine Susanne Falk, Hermann Einsele, Sebastian Wurster, Götz Ulrich Grigoleit, Götz Ulrich Grigoleit, Sabrina Kraus   +15 more
doaj   +1 more source

Letermovir for Cytomegalovirus Prophylaxis in Lung Transplant Patients with Valganciclovir-Induced Leukopenia

Transplantology, 2021
Cytomegalovirus (CMV) prophylaxis with valganciclovir is the standard of practice in most transplant centers, but treatment-related leukopenia can limit valganciclovir’s use.
Arindam Singha, Pamela K. Burcham, April Logan, Zeinab El Boghdadly, Molly M. Howsare, David R. Nunley, Mark E. Lustberg, Brian C. Keller   +7 more
doaj   +1 more source

Use of Letermovir for CMV Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation: Review of the Literature and Single-Center Real-Life Experience

Hemato, 2023
Cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplant (allo-HSCT) is mainly due to an increase of latent viremia in previously exposed patients.
Jessica Gill, Davide Stella, Irene Dogliotti, Chiara Dellacasa, Luisa Giaccone, Alessandro Busca   +5 more
doaj   +1 more source

Letermovir prophylaxis for cytomegalovirus reactivation in children who underwent hematopoietic stem cell transplantation: A single-institute experience in Taiwan

Journal of Microbiology, Immunology and Infection, 2022
From January 2019 to May 2021, 11 children underwent allogeneic stem cell transplantation at our institute. Four of them received letermovir for cytomegalovirus prophylaxis.
Chao-Neng Cheng, Sin-Syue Li, Yun-Hsuan Yeh, Ching-Fen Shen, Jiann-Shiuh Chen   +4 more
doaj   +1 more source